CELL TREATMENT STOPS PARKINSON
NTCELL stops Parkinson’s disease progression
one year after treatment
Over a year after treatment all four patients who took part in Living Cell Technologies Limited’s Phase I/IIa clinical study of NTCELL® for Parkinson’s disease remain well, and at 58 weeks post-implant there are no safety concerns.
In all four patients NTCELL treatment has stopped the progression of Parkinson’s disease as measured by globally accepted and validated neurological rating scales.
NTCELL® is a choroid plexus cell product with the potential to treat neurodegenerative diseases. Choroid plexus cells help produce cerebrospinal fluid as well as a range of neurotrophins (nerve growth factors) that have been shown to protect against neuron (nerve) cell death in animal models of disease.
Moreover, as the chart below shows, after 58 weeks there is a clinically and statistically significant improvement in all the patients’ neurological score from their pre-implant baseline.
Parkinson’s disease progression is measured by a neurological rating scale, Unified Parkinson’s Disease Rating Scale (UPDRS). The UPDRS score increases by approximately 4 to 5 points each year as Parkinson’s disease progresses.
NTCELL’s ability to decrease UPDRS by an average of 16 points after 58 weeks is clinically significant, representing a 3 to 4 year reversal of neurological deterioration. In the first patient the improvement is maintained at 74 weeks after NTCELL implant.
Dr Ken Taylor, chief executive, says the sustained improvement of the patients is pleasing, particularly as no other treatment has been able to maintain long term reversal of the effects of Parkinson’s disease.
“We are delighted with the continued positive outcome of the study. It certainly adds anticipation and motivation to our authorised Phase IIb study, which we plan to initiate on 24 February.”
The planned Phase IIb study aims to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group.
“Our goal is to obtain provisional consent and launch NTCELL as the first disease modifying treatment for Parkinson’s disease in 2017,” says Dr Taylor.